WAY — Waystar Holding Corp.

Waystar Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $269 million, a 12% year-over-year increase.
• Adjusted EBITDA: $113 million, up 17% year-over-year, with an adjusted EBITDA margin of 42%.
• Net Revenue Retention Rate (NRR): 113%, benefiting from clients impacted by a competitor's cyber event in early 2024.
• Client Growth: 1,306 clients generating over $100,000 in trailing 12-month revenue, an 11% increase year-over-year.
• Cash Flow: Unlevered free cash flow of $96 million, with an 85% conversion ratio to adjusted EBITDA.
• Leverage Ratio: 1.9x at the end of Q3, projected to be 3.4x post-Iodine acquisition.

2. Strategic Updates and Business Highlights

• Acquisition of Iodine Software: Completed on October 1, 2025, expected to expand the total addressable market by over 15% and accelerate product innovation.
• Client Conference: Waystar True North hosted over 500 revenue cycle leaders, showcasing innovations and client success stories.
• Product Innovations: Launched new AI-powered capabilities addressing denial prevention and patient financial care, enhancing operational efficiency for clients.
• Market Position: Waystar is recognized as the #1 trusted vendor in the industry, with high client satisfaction and Net Promoter Scores.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to $1.085 billion - $1.093 billion, reflecting a 15% year-over-year growth rate, including approximately $30 million from Iodine in Q4.
• Adjusted EBITDA Guidance: Increased to $451 million - $455 million, maintaining a 42% margin.
• Long-Term Strategy: Focus on leveraging AI to enhance product offerings and operational efficiencies, with a commitment to maintaining a disciplined growth approach.

4. Challenges and Points of Concern

• Patient Utilization Trends: Noted a return to historical growth rates, with volume-based revenue decreasing 4% sequentially, raising questions about future growth sustainability.
• Data Fragmentation: A significant challenge in the healthcare industry, limiting AI effectiveness due to siloed and unstructured data.
• Competitive Pressures: Increasing competition from EHR vendors integrating AI into their offerings, necessitating a strong differentiation strategy for Waystar.
• Cybersecurity Risks: As AI becomes more integrated into healthcare processes, maintaining secure and compliant data management remains critical.

5. Notable Q&A Insights

• Client Feedback on Iodine: Positive sentiment from clients about the Iodine acquisition, with expectations for enhanced integration and capabilities.
• Sales Cycle Dynamics: Discussions around the potential for accelerated sales cycles as clients seek to modernize legacy processes with AI-enabled solutions.
• Monetization Strategy: Waystar is exploring multiple avenues for monetizing AI, including pricing to value and introducing new software modules.
• Internal AI Utilization: Waystar is actively deploying AI to enhance internal efficiencies, with over 100 use cases being piloted to improve productivity and client experiences.

Overall, Waystar demonstrated strong financial performance and strategic momentum in Q3 2025, while also acknowledging challenges related to market competition and operational hurdles. The integration of Iodine is seen as a pivotal move to enhance growth and innovation.